請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/9813
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 邱麗珠 | |
dc.contributor.author | Chia-Hsu Lee | en |
dc.contributor.author | 李家旭 | zh_TW |
dc.date.accessioned | 2021-05-20T20:42:54Z | - |
dc.date.available | 2013-08-08 | |
dc.date.available | 2021-05-20T20:42:54Z | - |
dc.date.copyright | 2008-08-08 | |
dc.date.issued | 2008 | |
dc.date.submitted | 2008-07-22 | |
dc.identifier.citation | Adam JA, Menheere PP, van Dielen FM, Soeters PB, Buurman WA, Greve JW. 2002. Decreased plasma orexin-A levels in obese individuals. International Journal of Obesity & Related Metabolic Disorders: Journal of the International Association for the Study of Obesity 26(2):274-6.
Akbari E, Motamedi F, Naghdi N, Noorbakhshnia M. 2008. The effect of antagonization of orexin 1 receptors in CA1 and dentate gyrus regions on memory processing in passive avoidance task. Behavioural Brain Research 187(1):172-7. Akbari E, Naghdi N, Motamedi F. 2006. Functional inactivation of orexin 1 receptors in CA1 region impairs acquisition, consolidation and retrieval in Morris water maze task. Behavioural Brain Research 173(1):47-52. Akbari E, Naghdi N, Motamedi F. 2007. The selective orexin 1 receptor antagonist SB-334867-A impairs acquisition and consolidation but not retrieval of spatial memory in Morris water maze. Peptides 28(3):650-6. Aou S, Li XL, Li AJ, Oomura Y, Shiraishi T, Sasaki K, Imamura T, Wayner MJ. 2003. Orexin-A (hypocretin-1) impairs Morris water maze performance and CA1-Schaffer collateral long-term potentiation in rats. Neuroscience 119(4):1221-8. Arai A, Black J, Lynch G. 1994. Origins of the variations in long-term potentiation between synapses in the basal versus apical dendrites of hippocampal neurons. Hippocampus 4(1):1-9. Asahi S, Egashira S, Matsuda M, Iwaasa H, Kanatani A, Ohkubo M, Ihara M, Morishima H. 2003. Development of an orexin-2 receptor selective agonist, [Ala11, D-Leu15]orexin-B. Bioorganic & Medicinal Chemistry Letters 13(1):111-3. Baranowska B, Wolinska-Witort E, Martynska L, Chmielowska M, Baranowska-Bik A. 2005. Plasma orexin A, orexin B, leptin, neuropeptide Y (NPY) and insulin in obese women. Neuro Endocrinol Lett 26(4):293-6. Bayazitov IT, Richardson RJ, Fricke RG, Zakharenko SS, Jaeger LB, Farr SA, Banks WA, Morley JE. 2007. Slow presynaptic and fast postsynaptic components of compound long-term potentiation. Journal of neuroscience 24;27(43):11510-21. Beuckmann CT, Yanagisawa M. 2002. Orexins: from neuropeptides to energy homeostasis and sleep/wake regulation. Journal of Molecular Medicine 80(6):329-42. Bingham S, Davey PT, Babbs AJ, Irving EA, Sammons MJ, Wyles M, Jeffrey P, Cutler L, Riba I, Johns A and others. 2001. Orexin-A, an hypothalamic peptide with analgesic properties. Pain 92(1-2):81-90. Bongsebandhu-phubhakdi S, Manabe T. 2007. The neuropeptide nociceptin is a synaptically released endogenous inhibitor of hippocampal long-term potentiation. Journal of Neuroscience 27(18):4850-8. Borgland SL, Taha SA, Sarti F, Fields HL, Bonci A. 2006. Orexin A in the VTA is critical for the induction of synaptic plasticity and behavioral sensitization to cocaine. Neuron 49(4):589-601. Boutrel B, Kenny PJ, Specio SE, Martin-Fardon R, Markou A, Koob GF, de Lecea L. 2005. Role for hypocretin in mediating stress-induced reinstatement of cocaine-seeking behavior. Proceedings of the National Academy of Sciences of the United States of America 102(52):19168-73. Bronsky J, Nedvidkova J, Zamrazilova H, Pechova M, Chada M, Kotaska K, Nevoral J, Prusa R. 2007. Dynamic changes of orexin A and leptin in obese children during body weight reduction. Physiology Research 56(1):89-96. Brown RE, Sergeeva OA, Eriksson KS, Haas HL. 2002. Convergent excitation of dorsal raphe serotonin neurons by multiple arousal systems (orexin/hypocretin, histamine and noradrenaline). Journal of Neuroscience 22(20):8850-9. Burdakov D, Gerasimenko O, Verkhratsky A. 2005. Physiological changes in glucose differentially modulate the excitability of hypothalamic melanin-concentrating hormone and orexin neurons in situ. Journal of Neuroscience 25(9):2429-33. Capocchi G, Zampolini M, Larson J. 1992. Theta burst stimulation is optimal for induction of LTP at both apical and basal dendritic synapses on hippocampal CA1 neurons. Brain Res 591(2):332-6. Chabas D, Foulon C, Gonzalez J, Nasr M, Lyon-Caen O, Willer JC, Derenne JP, Arnulf I. 2007. Eating disorder and metabolism in narcoleptic patients. Sleep 30(10):1267-73. Chemelli RM, Willie JT, Sinton CM, Elmquist JK, Scammell T, Lee C, Richardson JA, Williams SC, Xiong Y, Kisanuki Y and others. 1999. Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation. Cell 98(4):437-51. Chen CT, Dun SL, Kwok EH, Dun NJ, Chang JK. 1999. Orexin A-like immunoreactivity in the rat brain. Neuroscience Letters 260(3):161-4. Cheng JK, Hwang LL, Chou RCC, Chiou LC. 2005. Analgesic effects of orexins. . Journal of Neuropathic Pain & Symptom Palliation 1:47-53. Chiou LC, Liao YY, Fan PC, Kuo PH, Wang CH, Riemer C, Prinssen EP. 2007. Nociceptin/orphanin FQ peptide receptors: pharmacology and clinical implications. Current Drug Targets 8(1):117-35. Cluderay JE, Harrison DC, Hervieu GJ. 2002. Protein distribution of the orexin-2 receptor in the rat central nervous system. Regulatory Peptides 104(1-3):131-44. Cutler DJ, Morris R, Sheridhar V, Wattam TA, Holmes S, Patel S, Arch JR, Wilson S, Buckingham RE, Evans ML and others. 1999. Differential distribution of orexin-A and orexin-B immunoreactivity in the rat brain and spinal cord. Peptides 20(12):1455-70. Dalal MA, Schuld A, Haack M, Uhr M, Geisler P, Eisensehr I, Noachtar S, Pollmacher T. 2001. Normal plasma levels of orexin A (hypocretin-1) in narcoleptic patients. Neurology 56(12):1749-51. Date Y, Mondal MS, Matsukura S, Nakazato M. 2000. Distribution of orexin-A and orexin-B (hypocretins) in the rat spinal cord. Neuroscience Letters 288(2):87-90. de Lecea L, Kilduff TS, Peyron C, Gao X, Foye PE, Danielson PE, Fukuhara C, Battenberg EL, Gautvik VT, Bartlett FS, 2nd and others. 1998. The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity. Proceedings of the National Academy of Sciences of the United States of America 95(1):322-7. de Lecea L, Sutcliffe JG. 1999. The hypocretins/orexins: novel hypothalamic neuropeptides involved in different physiological systems. Cellular & Molecular Life Sciences 56(5-6):473-80. Delaney KR, Tank DW. 1994. A quantitative measurement of the dependence of short-term synaptic enhancement on presynaptic residual calcium. Journal of Neuroscience 14(10):5885-902. Dun NJ, Le Dun S, Chen CT, Hwang LL, Kwok EH, Chang JK. 2000. Orexins: a role in medullary sympathetic outflow. Regulatory Peptides 96(1-2):65-70. Elmquist JK, Elias CF, Saper CB. 1999. From lesions to leptin: hypothalamic control of food intake and body weight. Neuron 22(2):221-32. Engelmann M, Landgraf R, Wotjak CT. 2004. The hypothalamic-neurohypophysial system regulates the hypothalamic-pituitary-adrenal axis under stress: an old concept revisited. Frontiers in Neuroendocrinology 25(3-4):132-49. Fadel J, Deutch AY. 2002. Anatomical substrates of orexin-dopamine interactions: lateral hypothalamic projections to the ventral tegmental area. Neuroscience 111(2):379-87. Hagan JJ, Leslie RA, Patel S, Evans ML, Wattam TA, Holmes S, Benham CD, Taylor SG, Routledge C, Hemmati P and others. 1999. Orexin A activates locus coeruleus cell firing and increases arousal in the rat. Proceedings of the National Academy of Sciences of the United States of America 96(19):10911-6. Hara J, Beuckmann CT, Nambu T, Willie JT, Chemelli RM, Sinton CM, Sugiyama F, Yagami K, Goto K, Yanagisawa M and others. 2001. Genetic ablation of orexin neurons in mice results in narcolepsy, hypophagia, and obesity. Neuron 30(2):345-54. Hara J, Yanagisawa M, Sakurai T. 2005. Difference in obesity phenotype between orexin-knockout mice and orexin neuron-deficient mice with same genetic background and environmental conditions. Neuroscience Letters 380(3):239-42. Harris GC, Wimmer M, Aston-Jones G. 2005. A role for lateral hypothalamic orexin neurons in reward seeking. Nature 437(7058):556-9. Heinonen MV, Purhonen AK, Miettinen P, Paakkonen M, Pirinen E, Alhava E, Akerman K, Herzig KH. 2005. Apelin, orexin-A and leptin plasma levels in morbid obesity and effect of gastric banding. Regulatory Peptide 130(1-2):7-13. Hervieu GJ, Cluderay JE, Harrison DC, Roberts JC, Leslie RA. 2001. Gene expression and protein distribution of the orexin-1 receptor in the rat brain and spinal cord. Neuroscience 103(3):777-97. Hirose M, Egashira S, Goto Y, Hashihayata T, Ohtake N, Iwaasa H, Hata M, Fukami T, Kanatani A, Yamada K. 2003. N-acyl 6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline: the first orexin-2 receptor selective non-peptidic antagonist. Bioorganic & Medicinal Chemistry Letters 13(24):4497-9. Hoang QV, Bajic D, Yanagisawa M, Nakajima S, Nakajima Y. 2003. Effects of orexin (hypocretin) on GIRK channels. Journal of Neurophysiology 90(2):693-702. Honda Y, Doi Y, Ninomiya R, Ninomiya C. 1986. Increased frequency of non-insulin-dependent diabetes mellitus among narcoleptic patients. Sleep 9(1 Pt 2):254-9. Huang ZL, Qu WM, Li WD, Mochizuki T, Eguchi N, Watanabe T, Urade Y, Hayaishi O. 2001. Arousal effect of orexin A depends on activation of the histaminergic system. Proceedings of the National Academy of Sciences of the United States of America 98(17):9965-70. Ida T, Nakahara K, Murakami T, Hanada R, Nakazato M, Murakami N. 2000. Possible involvement of orexin in the stress reaction in rats. Biochemical & Biophysical Research Communications 270(1):318-23. Ishii K, Adachi Y, Hatanaka M, Sakamoto H, Furuyama J. 1990. Spontaneous and cAMP-dependent induction of a resting phase and neurite formation in cell hybrids between human neuroblastoma cells and thymidine auxotrophs of rat nerve-like cells. Journal of Cellular Physiology 143(3):569-76. Jaeger LB, Farr SA, Banks WA, Morley JE. 2002. Effects of orexin-A on memory processing. Peptides 23(9):1683-8. Jones DN, Gartlon J, Parker F, Taylor SG, Routledge C, Hemmati P, Munton RP, Ashmeade TE, Hatcher JP, Johns A and others. 2001. Effects of centrally administered orexin-B and orexin-A: a role for orexin-1 receptors in orexin-B-induced hyperactivity. Psychopharmacology 153(2):210-218. Kayaba Y, Nakamura A, Kasuya Y, Ohuchi T, Yanagisawa M, Komuro I, Fukuda Y, Kuwaki T. 2003. Attenuated defense response and low basal blood pressure in orexin knockout mice. American Journal of Physiology - Regulatory Integrative & Comparative Physiology 285(3):R581-93. Kilduff TS, Peyron C. 2000. The hypocretin/orexin ligand-receptor system: implications for sleep and sleep disorders. Trends in Neurosciences 23(8):359-65. Kirchgessner AL, Liu M. 1999. Orexin synthesis and response in the gut. Neuron 24(4):941-51. Kiyashchenko LI, Mileykovskiy BY, Lai YY, Siegel JM. 2001. Increased and decreased muscle tone with orexin (hypocretin) microinjections in the locus coeruleus and pontine inhibitory area. Journal of Neurophysiology 85(5):2008-16. Kopp C, Longordo F, Nicholson JR, Luthi A. 2006. Insufficient sleep reversibly alters bidirectional synaptic plasticity and NMDA receptor function. Journal of Neuroscience 26(48):12456-65. Korogod N, Lou X, Schneggenburger R. 2005. Presynaptic Ca2+ requirements and developmental regulation of posttetanic potentiation at the calyx of Held. Journal of Neuroscience 25(21):5127-37. Korotkova TM, Sergeeva OA, Eriksson KS, Haas HL, Brown RE. 2003. Excitation of ventral tegmental area dopaminergic and nondopaminergic neurons by orexins/hypocretins. Journal of Neuroscience 23(1):7-11. Kotz CM. 2006. Integration of feeding and spontaneous physical activity: role for orexin. Physiology & Behavior 88(3):294-301. Kukkonen JP, Akerman KE. 2001. Orexin receptors couple to Ca2+ channels different from store-operated Ca2+ channels. Neuroreport 12(9):2017-20. Kukkonen JP, Åkerman KEO. 2005. Intracellular Signal Pathways Utilized by the Hypocretin/Orexin Receptors Hypocretins-Integrators of Physiological Functions 221-231. Kukkonen JP, Holmqvist T, Ammoun S, Akerman KE. 2002. Functions of the orexinergic/hypocretinergic system. American Journal of Physiology - Cell Physiology 283(6):C1567-91. Kunii K, Yamanaka A, Nambu T, Matsuzaki I, Goto K, Sakurai T. 1999. Orexins/hypocretins regulate drinking behaviour. Brain Research 842(1):256-61. Lammers GJ, Pijl H, Iestra J, Langius JA, Buunk G, Meinders AE. 1996. Spontaneous food choice in narcolepsy. Sleep 19(1):75-6. Larsson KP, Peltonen HM, Bart G, Louhivuori LM, Penttonen A, Antikainen M, Kukkonen JP, Akerman KE. 2005. Orexin-A-induced Ca2+ entry: evidence for involvement of trpc channels and protein kinase C regulation. Journal of Biological Chemistry 280(3):1771-81. Lauri SE, Palmer M, Segerstrale M, Vesikansa A, Taira T, Collingridge GL. 2007. Presynaptic mechanisms involved in the expression of STP and LTP at CA1 synapses in the hippocampus. Neuropharmacology 52(1):1-11. Lieberman DN, Mody I. 1994. Regulation of NMDA channel function by endogenous Ca(2+)-dependent phosphatase. Nature 369(6477):235-9. Lin L, Faraco J, Li R, Kadotani H, Rogers W, Lin X, Qiu X, de Jong PJ, Nishino S, Mignot E. 1999. The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene. Cell 98(3):365-76. Liu RJ, van den Pol AN, Aghajanian GK. 2002. Hypocretins (orexins) regulate serotonin neurons in the dorsal raphe nucleus by excitatory direct and inhibitory indirect actions. Journal of Neuroscience 22(21):9453-64. Lopez M, Senaris R, Gallego R, Garcia-Caballero T, Lago F, Seoane L, Casanueva F, Dieguez C. 1999. Orexin receptors are expressed in the adrenal medulla of the rat. Endocrinology 140(12):5991-4. Lou XM, Duan GC, Chen J, Zhou Y, Hu QY, Heng ZC. 2006. Blood leptin, orexins and NPY levels and their relations in obese children. Sichuan Da Xue Xue Bao Yi Xue Ban 37(4):621-4. Lu WY, Jackson MF, Bai D, Orser BA, MacDonald JF. 2000. In CA1 pyramidal neurons of the hippocampus protein kinase C regulates calcium-dependent inactivation of NMDA receptors. Journal of Neuroscience 20(12):4452-61. Lubkin M, Stricker-Krongrad A. 1998. Independent feeding and metabolic actions of orexins in mice. Biochemical & Biophysical Research Communications 253(2):241-5. Lund PE, Shariatmadari R, Uustare A, Detheux M, Parmentier M, Kukkonen JP, Akerman KE. 2000. The orexin OX1 receptor activates a novel Ca2+ influx pathway necessary for coupling to phospholipase C. Journal of biological chemistry 275(40):30806-12. Marcus JN, Aschkenasi CJ, Lee CE, Chemelli RM, Saper CB, Yanagisawa M, Elmquist JK. 2001. Differential expression of orexin receptors 1 and 2 in the rat brain. Journal of comparative neurology 435(1):6-25. Matsuki T, Sakurai T. 2008. Orexins and orexin receptors: from molecules to integrative physiology. Results and problems in cell differentiation 46:27-55. Mazzocchi G, Malendowicz LK, Aragona F, Rebuffat P, Gottardo L, Nussdorfer GG. 2001. Human pheochromocytomas express orexin receptor type 2 gene and display an in vitro secretory response to orexins A and B. Journal of Clinical Endocrinology & Metabolism 86(10):4818-21. Mieda M, Yanagisawa M. 2002. Sleep, feeding, and neuropeptides: roles of orexins and orexin receptors. Current Opinion in Neurobiology 12(3):339-45. Mintz EM, van den Pol AN, Casano AA, Albers HE. 2001. Distribution of hypocretin-(orexin) immunoreactivity in the central nervous system of Syrian hamsters (Mesocricetus auratus). Journal of Chemical Neuroanatomy 21(3):225-38. Moriguchi T, Sakurai T, Nambu T, Yanagisawa M, Goto K. 1999. Neurons containing orexin in the lateral hypothalamic area of the adult rat brain are activated by insulin-induced acute hypoglycemia. Neuroscience Letters 264(1-3):101-4. Nakamura T, Uramura K, Nambu T, Yada T, Goto K, Yanagisawa M, Sakurai T. 2000. Orexin-induced hyperlocomotion and stereotypy are mediated by the dopaminergic system. Brain Researchearch 873(1):181-7. Nambu T, Sakurai T, Mizukami K, Hosoya Y, Yanagisawa M, Goto K. 1999a. Distribution of orexin neurons in the adult rat brain. Brain Research 827(1-2):243-60. Nambu T, Sakurai T, Mizukami K, Hosoya Y, Yanagisawa M, Goto K. 1999b. Distribution of orexin neurons in the adult rat brain. Brain Research 827(1-2):243-60. Narita M, Nagumo Y, Hashimoto S, Narita M, Khotib J, Miyatake M, Sakurai T, Yanagisawa M, Nakamachi T, Shioda S and others. 2006. Direct involvement of orexinergic systems in the activation of the mesolimbic dopamine pathway and related behaviors induced by morphine. Journal of Neuroscience 26(2):398-405. Nishino S, Ripley B, Overeem S, Lammers GJ, Mignot E. 2000. Hypocretin (orexin) deficiency in human narcolepsy. Lancet 355(9197):39-40. Pedrazzoli M, D'Almeida V, Martins PJ, Machado RB, Ling L, Nishino S, Tufik S, Mignot E. 2004. Increased hypocretin-1 levels in cerebrospinal fluid after REM sleep deprivation. Brain Research 995(1):1-6. Peyron C, Tighe DK, van den Pol AN, de Lecea L, Heller HC, Sutcliffe JG, Kilduff TS. 1998. Neurons containing hypocretin (orexin) project to multiple neuronal systems. Journal of Neuroscience 18(23):9996-10015. Philpot BD, Espinosa JS, Bear MF. 2003. Evidence for altered NMDA receptor function as a basis for metaplasticity in visual cortex. Journal of Neuroscience 23(13):5583-8. Pu S, Jain MR, Kalra PS, Kalra SP. 1998. Orexins, a novel family of hypothalamic neuropeptides, modulate pituitary luteinizing hormone secretion in an ovarian steroid-dependent manner. Regulatory Peptides 78(1-3):133-6. Rosenmund C, Feltz A, Westbrook GL. 1995. Calcium-dependent inactivation of synaptic NMDA receptors in hippocampal neurons. J Neurophysiol 73(1):427-30. Rycroft BK, Gibb AJ. 2004. Inhibitory interactions of calcineurin (phosphatase 2B) and calmodulin on rat hippocampal NMDA receptors. Neuropharmacology 47(4):505-14. Sakamoto F, Yamada S, Ueta Y. 2004. Centrally administered orexin-A activates corticotropin-releasing factor-containing neurons in the hypothalamic paraventricular nucleus and central amygdaloid nucleus of rats: possible involvement of central orexins on stress-activated central CRF neurons. Regulatory Peptides 118(3):183-91. Sakurai T, Amemiya A, Ishii M, Matsuzaki I, Chemelli RM, Tanaka H, Williams SC, Richardson JA, Kozlowski GP, Wilson S and others. 1998a. Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. Cell 92(4):573-85. Sakurai T, Amemiya A, Ishii M, Matsuzaki I, Chemelli RM, Tanaka H, Williams SC, Richarson JA, Kozlowski GP, Wilson S and others. 1998b. Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. Cell 92(5):1 page following 696. Schuld A, Hebebrand J, Geller F, Pollmacher T. 2000. Increased body-mass index in patients with narcolepsy. Lancet 355(9211):1274-5. Selbach O, Doreulee N, Bohla C, Eriksson KS, Sergeeva OA, Poelchen W, Brown RE, Haas HL. 2004. Orexins/hypocretins cause sharp wave- and theta-related synaptic plasticity in the hippocampus via glutamatergic, gabaergic, noradrenergic, and cholinergic signaling. Neuroscience 127(2):519-28. Shirasaka T, Nakazato M, Matsukura S, Takasaki M, Kannan H. 1999. Sympathetic and cardiovascular actions of orexins in conscious rats. American Journal of Physiology 277(6 Pt 2):R1780-5. Smart D, Sabido-David C, Brough SJ, Jewitt F, Johns A, Porter RA, Jerman JC. 2001. SB-334867-A: the first selective orexin-1 receptor antagonist. British Journal of Pharmacology 132(6):1179-82. Spinazzi R, Andreis PG, Rossi GP, Nussdorfer GG. 2006. Orexins in the regulation of the hypothalamic-pituitary-adrenal axis. Pharmacological Reviews 58(1):46-57. Spinazzi R, Ziolkowska A, Neri G, Nowak M, Rebuffat P, Nussdorfer GG, Andreis PG, Malendowicz LK. 2005. Orexins modulate the growth of cultured rat adrenocortical cells, acting through type 1 and type 2 receptors coupled to the MAPK p42/p44- and p38-dependent cascades. International Journal of Molecular Medicine 15(5):847-52. Stadel JM, Wilson S, Bergsma DJ. 1997. Orphan G protein-coupled receptors: a neglected opportunity for pioneer drug discovery. Trends in Pharmacological Sciences 18(11):430-7. Takahashi N, Okumura T, Yamada H, Kohgo Y. 1999. Stimulation of gastric acid secretion by centrally administered orexin-A in conscious rats. Biochemical & Biophysical Research Communications 254(3):623-7. Telegdy G, Adamik A. 2002a. The action of orexin A on passive avoidance learning. Involvement of transmitters. Regulatory Peptides 104(1-3):105-10. Trivedi P, Yu H, MacNeil DJ, Van der Ploeg LH, Guan XM. 1998. Distribution of orexin receptor mRNA in the rat brain. FEBS Letters 438(1-2):71-5. Uramura K, Funahashi H, Muroya S, Shioda S, Takigawa M, Yada T. 2001. Orexin-a activates phospholipase C- and protein kinase C-mediated Ca2+ signaling in dopamine neurons of the ventral tegmental area. Neuroreport 12(9):1885-9. van den Pol AN. 1999. Hypothalamic hypocretin (orexin): robust innervation of the spinal cord. Journal of Neuroscience 19(8):3171-82. Wang C, Wang HG, Xie H, Pitt GS. 2008. Ca2+/CaM controls Ca2+-dependent inactivation of NMDA receptors by dimerizing the NR1 C termini. Journal of Neuroscience 28(8):1865-70. Wayner MJ, Armstrong DL, Phelix CF, Oomura Y. 2004. Orexin-A (Hypocretin-1) and leptin enhance LTP in the dentate gyrus of rats in vivo. Peptides 25(6):991-6. Wayner MJ, Chitwood R, Armstrong DL, Phelix C. 1997a. Ethanol affects hypothalamic neurons projecting to the hippocampus and inhibits dentate granule cell LTP. Alcohol 14(1):1-7. Wayner MJ, Phelix CF, Armstrong DL. 1997b. Lateral hypothalamic stimulation inhibits dentate granule cell LTP: direct connections. Brain Research Bullet 43(1):5-15. Wijker M, Wszolek ZK, Wolters EC, Rooimans MA, Pals G, Pfeiffer RF, Lynch T, Rodnitzky RL, Wilhelmsen KC, Arwert F. 1996. Localization of the gene for rapidly progressive autosomal dominant parkinsonism and dementia with pallido-ponto-nigral degeneration to chromosome 17q21. Human Molecular Genetics 5(1):151-4. Wilhelmsen KC, Lynch T, Pavlou E, Higgins M, Nygaard TG. 1994. Localization of disinhibition-dementia-parkinsonism-amyotrophy complex to 17q21-22. American Journal of Human Genetics 55(6):1159-65. Yamanaka A, Beuckmann CT, Willie JT, Hara J, Tsujino N, Mieda M, Tominaga M, Yagami K, Sugiyama F, Goto K and others. 2003. Hypothalamic orexin neurons regulate arousal according to energy balance in mice. Neuron 38(5):701-13. Yamanaka A, Tsujino N, Funahashi H, Honda K, Guan JL, Wang QP, Tominaga M, Goto K, Shioda S, Sakurai T. 2002. Orexins activate histaminergic neurons via the orexin 2 receptor. Biochemical & Biophysical Research Communications 290(4):1237-45. Yang B, Samson WK, Ferguson AV. 2003. Excitatory effects of orexin-A on nucleus tractus solitarius neurons are mediated by phospholipase C and protein kinase C. Journal of Neuroscience 23(15):6215-22. Zhang W, Sakurai T, Fukuda Y, Kuwaki T. 2006. Orexin neuron-mediated skeletal muscle vasodilation and shift of baroreflex during defense response in mice. American Journal of Physiology - Regulatory Integrative & Comparative Physiology 290(6):R1654-63. Zhu Y, Miwa Y, Yamanaka A, Yada T, Shibahara M, Abe Y, Sakurai T, Goto K. 2003. Orexin receptor type-1 couples exclusively to pertussis toxin-insensitive G-proteins, while orexin receptor type-2 couples to both pertussis toxin-sensitive and -insensitive G-proteins. Journal of Pharmacological Sciences 92(3):259-66. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/9813 | - |
dc.description.abstract | 分佈於下視丘為主的orexin neurons會經由腦部廣泛投射的軸突釋出orexins, 可分為orexnin A (hypocretin 1)和orexin B (hypocretin 2),會與orexin receptors結合。這個受體是在1998年被去孤兒化的G蛋白偶合受體,又分做兩種亞型,orexin 1 receptor (OX1R)和orexin 2 receptor (OX2R)。OX1R 對於 orexin A 的親和力比orexin B高,但是OX2R對於兩者的親和力則相似。這兩種orexin receptors的在腦中分佈極廣,並與自下視丘orexin neurons投射出的軸突所釋放的orexins接合,被証實與許多生理病理的機轉有關。hippocampus 中也有orexin neurons投射的軸突和orexin receptor的分布,且在許多以大鼠實驗對象的in vivo實驗中被證實會影響hippocampus 的突觸可塑性以及學習和記憶的表現。而以大鼠和小鼠的hippocampus 腦切片為實驗材料的in vivo實驗中,亦發現orexins有影響神經基礎突觸傳遞和突觸可塑性的現象。但orexin的角色仍眾說紛紜。因此,我們利用小鼠hippocampus 切片,觀察Schaffer Collateral-CA1區域中,外給orexins對基礎突觸傳遞和神經可塑性,包括長期增益現象和去增益現象,有何種影響。藉由在Schaffer Collateral至CA1的傳遞路徑上給予電刺激,CA1區域中的stratum radiatum進行胞外紀錄,所得到的場興奮性突觸後電位(fEPSPs)進行分析。長期增益現象(long term potentiation, LTP)是由高頻所引發刺激,我們所用的高頻刺激是由三個相隔15秒的theta頻率構成之刺激組成,每個 theta頻率的刺激是由4段100 HZ的高頻刺激構成,每段相隔200秒。去增益現象(depotentiation)則是在高頻刺激後四十分鐘,由連續的低頻(1 Hz)刺激15分鐘所引發。
灌流oirexin A (30, 100, 300 nM) 10分鐘後,所測得fEPSPs的斜率,並沒有影響基礎傳遞突觸。但orexin A會有意義的抑制LTP且具濃度相依性。高頻刺激後4分鐘內的fEPSPs的斜率變化,即後強直增強效應(post-tetanic potetanic, PTP),亦有輕微濃度相依的抑制情形,但不具統計上的差異。而各個濃度對去增益現象的影響,亦無統計上顯著差異。 灌流[Ala11, D-Leu15]-orexin B (3, 10, 30, 100, 300, 1000 nM) 10分鐘後,並沒有發現影響基礎傳遞突觸,在低濃度即可有意義的抑制LTP,但隨濃度的升高並無法增加抑制LTP的程度。觀察PTP,各組間不具統計上的差異。而各濃度對depotentiaion,亦無統計上的顯著影響。 將3 μM專一性OX1拮抗劑SB 334867與100 nM orexin A同時灌流,發現可部分反轉orexin A對LTP所造成的抑制。對PTP的輕微抑制亦有些許的反轉,但皆未達統計上顯著的差異。而各個濃度對depotentiation的影響,亦無統計上顯著差異。單獨投予SB 334867對基礎突觸傳遞、LTP、PTP和depotentiation並無影響。 再將3 μM專一性OX1拮抗劑SB 334867與300 nM [Ala11, D-Leu15]-orexin B同時灌流,發現可部分反轉[Ala11, D-Leu15]-orexin B對LTP所造成的抑制。對PTP並無影響。各組間對depotentiaion的影響,則無統計上顯著差異。 將30 μM專一性OX2拮抗劑 Compound 29與100 nM orexin A同時灌流,發現可部分反轉orexin A對LTP所造成的抑制,對PTP並無影響。各濃度對depotentiation的影響,則無統計上顯著差異。單獨投予Compound 29對基礎突觸傳遞、LTP、PTP和depotentiation並無影響。 再將30 μM專一性OX2拮抗劑 Compound 29 與300 nM [Ala11, D-Leu15]-orexin B同時灌流,發現可部分反轉[Ala11, D-Leu15]-orexin B對LTP所造成的抑制。對PTP並無影響。各組間對depotentiation的影響,則無統計上顯著差異。 在hippocampus CA1突觸會因極短的成對刺激(50 ms)後,鈣離子於突觸前堆積,而出現paired pulse facilitation的特性。計算paired pulse ratio (PPR),由第二個fEPSP斜率除與第一個fEPSP斜率,來評估突觸前神經傳遞物釋放的變化。我們發現在給予高頻刺激後40分鐘會有PPR下降(1.62±0.04 vs. 1.51±0.03, n=4),即突觸前神經傳遞物釋放增加。一般認為LTP是以突觸後NMDAR開啟來為主,而我們認為LTP應同時也有增加突觸前神經傳遞物釋放。orexin A (100 nM)並不影響基礎刺激下的PPR,但有輕微減少PPR下降程度的現象。 根據我們目前的實驗結果,在小鼠hippocampus CA1區域,發現orexin A和[Ala11, D-Leu15]-orexin B皆會部分抑制LTP,但並不影響depotentiation。對LTP的抑制效果,可能同時經由OX1R和OX2R,但OX1R可能佔有較大的比重。再者,突觸前的抑制效果可能很輕微,推測可能是在突觸後,藉由活化OX1R和OX2R活化PLC/PKC的途徑,造成抑制NMDA所媒介的電流為主。 | zh_TW |
dc.description.abstract | Orexins are a novel family of two hypothalamic peptides, consisting of orexin A and orexin B, which were also named hypocretin 1 and hypocretin 2, respectively. They were identified to be the endogenous agonists of an orphan GPCR in 1998, which was, therefore, named orexin receptor and consists of OX1 and OX2 receptors. OX1 receptors display higher affinity for orexin A than orexin B, while OX2 receptors have similar affinity for both orexin A and orexin B. Orexin-containing neurons are mostly localized in the lateral hypothalamus and send projections widely through the brain, including the hippocampus. Orexin A had been reported to affect learning and memory tasks and hippocampal synaptic plasticity in vivo, mostly in the rat, as well as affected synaptic plasticity of hippocampal slices of rats and mice in vitro. However, controversial results were reported. We, therefore, investigated the effects of orexins on the synaptic plasticity, long-term potentiation (LTP) and depotentiation, at Schaffer Collateral-CA1 synapses of mouse hippocampal slices. Field excitatory postsynaptic potentials (fEPSPs) were evoked by stimulating the Schaffer collateral pathway and recorded in the stratum radiatum of the CA1 region of hippocampal slices. LTP was induced by high frequency stimulation (HFS) which consisted of 3 trains of theta burst stimulation (TBS), separated by 15s. Each TBS consisted of 4 pulses at 100 Hz, separated by 200 ms. Depotentiation was induced by low frequency stimulation (LFS, 1Hz, 15 min) 40 min after HFS.
Orexin A (30-300 nM) had no effect on the baseline fEPSPs after 10 min treatment. Orexin A treated 10 min before and during HFS, decreased HFS-induced LTP dose-dependently. The magnitude of LTP (% of the baseline fEPSPs) 40 min after HFS was reduced by pretreatment with orexin A 100 nM and 300 nM. The magnitude of PTP (% of the baseline fEPSPs) 40 min after HFS was mild dose-dependently reduced by pretreatment with orexin A 30 nM, 100 nM and 300 nM. Depotentiation induced by LFS (expressed by the % restoration of the magnitude of LTP) 40 min after LFS was not different with orexin A. [Ala11, D-Leu15]-orexin B (3~1000nM) also had no effect on the baseline fEPSPs after 10 min treatment. [Ala11, D-Leu15]-orexin B treated 10 min before and during HFS, decreased HFS-induced LTP dose-dependently. The magnitude of LTP (% of the baseline fEPSPs) 40 min after HFS was reduced by pretreatment with [Ala11, D-Leu15]-orexin B 30 nM, 300 nM and 1000 nM. The magnitude of PTP (% of the baseline fEPSPs) 40 min after HFS had no different by pretreatment with [Ala11, D-Leu15]-orexin B. Depotentiation induced by LFS (expressed by the % restoration of the magnitude of LTP) 40 min after LFS was not different with [Ala11, D-Leu15]-orexin B. SB 334867 (3 μM), a selective OX1 receptor antagonist, partially antagonized the effect of orexin A. The magnitude of LTP (% of the baseline fEPSPs) in slices treated with orexin A+ SB-334867 was higher in slices with 100 nM orexin A, which was significantly lower than the control slices. The magnitude of PTP (% of the baseline fEPSPs) in slices treated with 100 nM orexin A had no significantly difference in slices with orexin A+ SB-334867, which was not significantly different with the control slices. SB-334867 alone had no effect on basal transmission, PTP, LTP and depotentiation. SB 334867 (3 μM) slightly antagonized the effect of [Ala11, D-Leu15]-orexin B. The magnitude of LTP (% of the baseline fEPSPs) in slices treated with 300 nM [Ala11, D-Leu15]-orexin B + SB 334867 was higher in slices with [Ala11, D-Leu15]-orexin B, which was significantly lower than the control slices. The magnitude of PTP (% of the baseline fEPSPs) in slices treated with 300 nM [Ala11, D-Leu15]-orexin B had no statistically significant difference in slices with [Ala11, D-Leu15]-orexin B + SB 334867, which was not significantly different with the control slices. SB 334867 alone had no effect on basal transmission, PTP, LTP and depotentiation. Compound 29 (30 μM), a selective OX2 receptor antagonist, partially antagonized the effect of 100 nM orexin A. The magnitude of LTP (% of the baseline fEPSPs) in slices treated with 100 nM orexin A + Compound 29 was higher in slices with 100 nM orexin A, which was significantly lower than the control slices. The magnitude of PTP (% of the baseline fEPSPs) in slices treated with 100 nM orexin A was no different in slices with orexin A + Compound 29, which was no significantly difference with the control slices. Compound 29 alone had no effect on basal transmission, PTP, LTP and depotentiation. Compound 29 (30 μM) slightly antagonized the effect of [Ala11, D-Leu15]-orexin B. The magnitude of LTP (% of the baseline fEPSPs) in slices treated with [Ala11, D-Leu15]-orexin B + Compound 29 (133±7.1%, n=5) was higher in slices with 300 nM [Ala11, D-Leu15]-orexin B (120.8±7.2%, n=5), which was significantly lower than the control slices (141.9±3.5%, n=16). The magnitude of PTP (% of the baseline fEPSPs) in slices treated with 300 nM [Ala11, D-Leu15]-orexin B (146.8±8.7%, n=5) was not significantly different in slices with [Ala11, D-Leu15]-orexin B + Compound 29 (186.5±28%, n=5), which had no significantly difference with the control slices (181.5±10.4 %, n=16). Compound 29 alone had no effect on basal transmission, PTP, LTP and depotentiation. Paired-pulse facilitation (PPF) of fEPSPs, a presynaptic phenomenon resulting from Ca2+ accumulation in the presynaptic terminals in response to stimulation by a pair pulses with short interval is induced by paired-pulse (50 ms interval) stimulation. The PPR during LTP decreased, as compared to basal PPF ratio (PPR), suggesting that increased presynaptic transmission plays a role in the LTP evoked by TBS in CA1 region of mouse hippocampal slices although this LTP is mostly mediated by NMDA receptors. Orexin A (100 nM) did not affect basal PPR but slightly reversed the PPR decreased during LTP. It is concluded that orexin A and [Ala11, D-Leu15]-orexin B decreased LTP but not affect depotentiation in CA1 region of mouse hippocampal slices. The impairment of LTP is mediated by both OX1 and OX2 receptors. The efficacy mediated by OX1 receptors is higher than that by OX2 receptors. It is suggested that presynaptic inhibition plays a little role in orexin-induced impairment; instead, postsynaptic NMDA receptor inhibition might contribute to this impairment through PLC/PKC pathway activated by OX1 and OX2 receptor activation. | en |
dc.description.provenance | Made available in DSpace on 2021-05-20T20:42:54Z (GMT). No. of bitstreams: 1 ntu-97-R95443016-1.pdf: 1765863 bytes, checksum: 98a4b5e76ce31fd09727b1f840bf6123 (MD5) Previous issue date: 2008 | en |
dc.description.tableofcontents | 一、 口試委員會審定書 ………………………… i
二、 誌謝 ………………………………………… ii 三、 縮寫表……………………………………… iii 四、 中文摘要……………………………………… vi 五、 英文摘要 …………………………………… iiv 六、 緒論…………………………………………… 1 七、 實驗材料及方法……………………………… 14 八、 實驗結果……………………………………… 19 九、 討論…………………………………………… 26 十、 結論…………………………………………… 32 十一、 圖表與附圖 ……………………………… 33 十二、 參考文獻 ………………………………… 53 | |
dc.language.iso | zh-TW | |
dc.title | Orexins對小鼠海馬迴神經突觸可塑性之研究 | zh_TW |
dc.title | Effect of orexins on synaptic plasiticity
of mouse hippocampal slices | en |
dc.type | Thesis | |
dc.date.schoolyear | 96-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 簡伯武,許桂森,黃玲玲,陶寶綠 | |
dc.subject.keyword | 海馬迴,Orexin,神經突觸可塑性,長期增益現象,去增益現象, | zh_TW |
dc.subject.keyword | hippocampus,orexin,neural plastisity,long term potentiaion,depotentiation, | en |
dc.relation.page | 62 | |
dc.rights.note | 同意授權(全球公開) | |
dc.date.accepted | 2008-07-22 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 藥理學研究所 | zh_TW |
顯示於系所單位: | 藥理學科所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-97-1.pdf | 1.72 MB | Adobe PDF | 檢視/開啟 |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。